The European Medicines Agency has approved pertuzumab (Perjeta, Roche/Genentech) for patients with HER2-positive metastatic breast cancer, the company announced today. Pertuzumab is approved in combination with trastuzumab (Herceptin, Roche/Genentech) and docetaxel for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
The most common (>30%) adverse reactions observed with pertuzumab in combination with trastuzumab plus docetaxel were neutropenia, nausea, fatigue, rash, and peripheral neuropathy. The most common (>2%) grade 3/4 adverse reactions were neutropenia, febrile neutropenia, leukopenia, diarrhea, peripheral neuropathy, anemia, asthenia, and fatigue.
Read more at Medscape